Lewis Nasr

538 total citations
27 papers, 139 citations indexed

About

Lewis Nasr is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, Lewis Nasr has authored 27 papers receiving a total of 139 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Public Health, Environmental and Occupational Health, 17 papers in Hematology and 15 papers in Genetics. Recurrent topics in Lewis Nasr's work include Acute Lymphoblastic Leukemia research (18 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Lewis Nasr is often cited by papers focused on Acute Lymphoblastic Leukemia research (18 papers), Chronic Myeloid Leukemia Treatments (16 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Lewis Nasr collaborates with scholars based in United States, Lebanon and France. Lewis Nasr's co-authors include Nicholas J. Short, Farhad Ravandi, Fadi Haddad, Elias Jabbour, Hagop M. Kantarjian, Nitin Jain, Tapan M. Kadia, Penny Fang, Rebecca Garris and Susan Wu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Lewis Nasr

24 papers receiving 139 citations

Peers

Countries citing papers authored by Lewis Nasr

Since Specialization

Citations

This map shows the geographic impact of Lewis Nasr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lewis Nasr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lewis Nasr more than expected).

Fields of papers citing papers by Lewis Nasr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lewis Nasr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lewis Nasr. The network helps show where Lewis Nasr may publish in the future.

Co-authorship network of co-authors of Lewis Nasr

This figure shows the co-authorship network connecting the top 25 collaborators of Lewis Nasr. A scholar is included among the top collaborators of Lewis Nasr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lewis Nasr. Lewis Nasr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab 2025 ·Journal of Hematology & Oncology ·Nicholas J. Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, (unknown), Sanam Loghavi, Lewis Nasr, Fadi Haddad, Jayastu Senapati, Rebecca Garris, Koichi Takahashi, Elias Jabbour	2
2	Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer 2024 ·Clinics and Research in Hepatology and Gastroenterology ·Hampig Raphaël Kourié, (unknown), (unknown), (unknown), Lewis Nasr, Fadi El Karak, (unknown), (unknown), (unknown), Nizar Bitar, (unknown), (unknown), Fadi Farhat, Jawad A. Makarem, Joseph Kattan, Julien Taı̈eb	1
3	Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia 2024 ·Cancer ·Elias Jabbour, Fadi Haddad, Koji Sasaki, Bing Z. Carter, Yesid Alvarado, (unknown), Lewis Nasr, Lucia Masárová, Naval Daver, Naveen Pemmaraju, Nicholas J. Short, Jeffrey Skinner, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia‐Manero, Farhad Ravandi, Ghayas C. Issa, Michael Andreeff, Hagop M. Kantarjian	8
4	Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL 2024 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Nicholas J. Short, Fadi Haddad, Nitin Jain, Xuelin Huang, Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Tapan M. Kadia, Naval Daver, Kelly S. Chien, Yesid Alvarado, Guillermo Garcia‐Manero, Ghayas C. Issa, Rebecca Garris, (unknown), Lewis Nasr, Farhad Ravandi, Elias Jabbour	23
5	Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung 2024 ·Advances in Radiation Oncology ·Susan Wu, Penny Fang, (unknown), (unknown), Kelsey L. Corrigan, Benjamin R. Schrank, Lewis Nasr, Dai Chihara, (unknown), Ranjit Nair, Raphaël Steiner, Preetesh Jain, Sattva S. Neelapu, Paolo Strati, Loretta J. Nastoupil, Bouthaina S. Dabaja, Chelsea C. Pinnix, Jillian R. Gunther	1
6	Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs 2024 ·Frontiers in Oncology ·(unknown), (unknown), Kelsey L. Corrigan, (unknown), Benjamin R. Schrank, Lewis Nasr, Dai Chihara, (unknown), Ranjit Nair, Preetesh Jain, Sattva S. Neelapu, Maria Alma Rodriguez, Paolo Strati, Loretta J. Nastoupil, Jillian R. Gunther, Bouthaina S. Dabaja, Chelsea C. Pinnix, Susan Wu, Penny Fang	0
7	Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase 2024 ·Cancer ·Fadi Haddad, Koji Sasaki, Lewis Nasr, Nicholas J. Short, Tapan M. Kadia, Sara Dellasala, Jörge E. Cortes, Franck E. Nicolini, Ghayas C. Issa, Elias Jabbour, Hagop M. Kantarjian	8
8	Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors 2024 ·Advances in Radiation Oncology ·(unknown), Lewis Nasr, Clark R. Andersen, Kathryn E. Marqueen, Jing Li, Chenyang Wang, Thomas H. Beckham, Nazanin Majd, Ashley Aaroe, Monica Loghin, Barbara O’Brien, Susan L. McGovern	2
9	Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Nicholas J. Short, Elias Jabbour, (unknown), Shilpa Paul, Branko Cuglievan, David McCall, (unknown), Nitin Jain, Fadi Haddad, Lewis Nasr, Kayleigh Marx, Caitlin R. Rausch, (unknown), Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian	11
10	Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Kelsey L. Corrigan, (unknown), Berthold Schrank, Lewis Nasr, Jillian R. Gunther, Paolo Strati, Sairah Ahmed, Luis Fayad, Ranjit Nair, Raphaël Steiner, Jason R. Westin, Loretta J. Nastoupil, (unknown), Chelsea C. Pinnix, Bouthaina S. Dabaja, Susan Wu, Penny Fang	0
11	S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY 2023 ·HemaSphere ·Nicholas J. Short, Elias Jabbour, Nitin Jain, Xuelin Huang, Walid Macaron, Lewis Nasr, Guillermo Montalban‐Bravo, Tapan M. Kadia, Naval Daver, Kelly S. Chien, Yesid Alvarado, Ghayas C. Issa, Fadi Haddad, (unknown), (unknown), Rebecca Garris, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian	2
12	“Dose-Dense” Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis 2023 ·Blood ·(unknown), Hagop M. Kantarjian, Shilpa Paul, Branko Cuglievan, David McCall, Nitin Jain, Fadi Haddad, Kayleigh Marx, Caitlin R. Rausch, (unknown), Lewis Nasr, (unknown), (unknown), Rebecca Garris, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Nicholas J. Short	0
13	AI-based online chat and the future of oncology care: a promising technology or a solution in search of a problem? 2023 ·Frontiers in Oncology ·Joseph Kassab, Lewis Nasr, Georges Gebrael, (unknown), (unknown), (unknown), (unknown), Fadi Nasr	10
14	Outcomes with Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Pts with Aggressive B Cell Lymphomas 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Susan Wu, Stephanie O. Dudzinski, Andrew Jallouk, (unknown), Lewis Nasr, (unknown), Jillian R. Gunther, Sairah Ahmed, Luis Fayad, Ranjit Nair, Raphaël Steiner, Jason R. Westin, (unknown), Bouthaina S. Dabaja, Paolo Strati, Loretta J. Nastoupil, (unknown), Penny Fang, Michael K. Rooney	2
15	P373: UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA 2023 ·HemaSphere ·Fadi Haddad, Elias Jabbour, (unknown), Nicholas J. Short, Lewis Nasr, Walid Macaron, (unknown), Farhad Ravandi, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Jovitta Jacob, (unknown), Christopher Loiselle, Anna Milton, Juan J. Rivera, Rebecca Garris, Hagop Kantarjian	1
16	P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY 2023 ·HemaSphere ·Nicholas J. Short, Elias Jabbour, Nitin Jain, Fadi Haddad, Musa Yılmaz, Lewis Nasr, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado, Abhishek Maiti, Walid Macaron, (unknown), (unknown), Rebecca Garris, Min Zhao, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian	2
17	S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL 2023 ·HemaSphere ·Fadi Haddad, Elias Jabbour, (unknown), Nicholas J. Short, Walid Macaron, (unknown), Lewis Nasr, Nitin Jain, (unknown), Koji Sasaki, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Guillermo Garcia‐Manero, Tapan M. Kadia, Sa A. Wang, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Hagop M. Kantarjian	3
18	Systemic AL amyloidosis: current approach and future direction 2023 ·Oncotarget ·Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, (unknown), (unknown), (unknown), (unknown), Faiz Anwer, Shahzad Raza, Chakra P. Chaulagain	16
19	Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study. 2023 ·Journal of Clinical Oncology ·Lewis Nasr, Nicholas J. Short, Jayastu Senapati, (unknown), Nitin Jain, Marina Konopleva, Walid Macaron, Farhad Ravandi, Courtney D. DiNardo, Koji Sasaki, Alessandra Ferrajoli, (unknown), (unknown), Jovitta Jacob, (unknown), Anna Milton, Christopher Loiselle, Rebecca Garris, Hagop M. Kantarjian, Elias Jabbour	2
20	Central Nervous System Prophylaxis and Treatment in Acute Leukemias 2022 ·Current Treatment Options in Oncology ·Susan Wu, Nicholas J. Short, Lewis Nasr, Bouthaina S. Dabaja, Penny Fang	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact